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Abstract: The lack of standardized terminology in
pelvic ﬂoor disorders (pelvic organ prolapse, urinary
incontinence, and fecal incontinence) is a major obstacle
to performing and interpreting research. The National
Institutes of Health convened the Terminology Work-
shop for Researchers in Female Pelvic Floor Disorders
to: (1) agree on standard terms for deﬁning conditions
and outcomes; (2) make recommendations for minimum
data collection for research; and (3) identify high priority
issues for future research. Pelvic organ prolapse was
deﬁned by physical examination staging using the
International Continence Society system. Stress urinary
incontinence was deﬁned by symptoms and testing;
‘cure’ was deﬁned as no stress incontinence symptoms,
negative testing, and no new problems due to interven-
tion. Overactive bladder was deﬁned as urinary
frequency and urgency, with and without urge incon-
tinence. Detrusor instability was deﬁned by cystometry.
For all urinary symptoms, deﬁning ‘improvement’ after
intervention was identiﬁed as a high priority. For fecal
incontinence, more research is needed before recom-
mendations can be made. A standard terminology for
research on pelvic ﬂoor disorders is presented and areas
of high priority for future research are identiﬁed.
Keywords: Clinical research; Fecal incontinence; Pelvic
organ prolapse; Standardization of terminology; Urinary
incontinence
Introduction
Female pelvic ﬂoor disorders are a wide variety of
clinical conditions, including urinary incontinence, fecal
incontinence, pelvic organ prolapse, sensory and
emptying abnormalities of the lower urinary tract, and
defecatory dysfunction. The most prevalent syndromes
(urinary incontinence, fecal incontinence and pelvic
organ prolapse) afﬂict women three to seven times more
often than men. The highest gender disparity is seen
between the ages of 45 and 69 years [1]. The earlier age
of onset in women magniﬁes the impact of pelvic ﬂoor
dysfunction on years of healthy life for women, who are
not only more likely to suffer from these problems but
who will spend more of the productive years of their
lives doing so. This is of particular relevance to all
clinicians who care for women. United States Census
projections estimate that the number of women aged 45–
69 years will increase from 27% of the total female
population in 2000 to 31% in 2020, and the number of
women aged 65 years and older in the year 2000 will
more than double by the year 2050 [2]. An analysis of
surgical procedure codes estimates that over 500 000
procedures are performed in the United States annually
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for prolapse and urinary incontinence [3]. These
numbers are certain to increase in accordance with the
predicted demographic changes.
Unfortunately, most of the literature describing the
results of these procedures does not meet contemporary
scientiﬁc standards for outcomes analyses. The 1996
Update of the Agency for Health Care Policy and
Research (AHCPR) Urinary Incontinence Clinical
Practice Guidelines concluded that the surgical literature
is deﬁcient in standards ‘for describing the patient
population, the type of incontinence, the methods for
accurate diagnosis, the techniques of the surgical
procedure, or the outcome in different domains’ [4].
The AHCPR conclusions are substantiated by a
comprehensive review by Black and Downs that
documented the poor quality of published literature on
surgical treatment of urinary incontinence and led the
authors to conclude that ‘recommendations as to the best
clinical practice cannot be based on scientiﬁc evidence’
[5]. Major methodological ﬂaws identiﬁed by Black and
Downs included variability in or a complete lack of case
deﬁnition for stress incontinence; failure to control for
confounding by random assignment, or to account for
unknown confounders by reporting their distribution;
lack of standardization of surgical technique; variability
in duration of follow-up; low or indeterminate external
validity (generalizability); inadequate power to detect
clinically important differences; lack of comprehensive
assessment of postoperative complications; and marked
variability in outcome assessment. Outcome assessment
was especially criticized for lack of blinding, for the use
of non-validated and non-standardized outcome mea-
sures, and for failure to obtain patients’ views through
the use of valid and reliable clinimetric methods and
questionnaires. Although these assertions applied speci-
ﬁcally to urinary incontinence, a similar assessment can
be made of literature on other pelvic ﬂoor disorders, such
as pelvic organ prolapse [6]. Most of these research
ﬂaws could be addressed initially by the institution of
speciﬁc standardized deﬁnitions of conditions and
criteria for the reporting of research studies.
Data are particularly deﬁcient in the description of
these conditions in women of minority race [7]. This
lack, coupled with the increased prevalence and severity
of conditions such as incontinence in the elderly,
particularly the institutionalized [8], and the projected
increase in racial diversity of the elderly [2], emphasize
the need for high-quality research in these women.
Geriatric populations may present a special challenge to
standard protocols and datasets because of logistic
limitations in their evaluation (e.g. the reliance on self-
reporting of symptoms in patients with dementia).
In September 1998, the National Institute of Child
Health and Human Development (NICHD), with other
Institutes at the National Institutes of Health (NIH),
sponsored a workshop to examine the state of basic,
epidemiological and clinical research addressing female
pelvic ﬂoor disorders. Lack of standardization of
terminology was identiﬁed as a critical obstacle to
performing high-quality research. To address this need,
in December 1999 another workshop was held by
NICHD and other NIH Institutes, bringing together
national and international researchers in the ﬁelds of
urology, gynecology and urogynecology, colorectal
surgery and nursing. The objectives of this meeting
were to deﬁne the various conditions of female pelvic
ﬂoor disorders; to develop a minimum dataset of
standard, validated baseline and follow-up variables in
multiple domains to be applied as uniformly as possible
in studies of these conditions; and to identify areas of
high priority for further research. Such standards are
crucial to the generation of reliable, cogent research on
the epidemiology, natural history and efﬁcacy of therapy
that will advance the ﬁeld of knowledge and improve the
level of care for all women with these disorders. The
goal of this report is to introduce these standards to
clinicians and researchers.
Acknowledgement of these standards in written
publications and scientiﬁc presentations should be
indicated in the Methods section with the following
statement: ‘Methods, deﬁnitions, and descriptions con-
form to the recommended standards except where
speciﬁcally noted’.
Minimum Data Set for All Pelvic Floor
Disorders
To ensure an adequate description of population
characteristics and allow comparison between studies,
it is important that a certain standard minimum amount
of data be collected when studying and reporting on
subjects with similar conditions. In general, scientiﬁc
evaluation of outcomes after intervention requires
comparison of the same assessments performed before
and after therapy. No simple measure can completely
express the outcome of therapeutic interventions. Both
subjective and objective measures should be included,
incorporating improvements and deteriorations in func-
tion as well as complications of the intervention. The
following applies to studies involving women with all
types of pelvic ﬂoor disorders; recommendations related
to speciﬁc conditions will be described in subsequent
sections. It should be emphasized that these recommen-
dations represent the minimum or most basic data
collection; additional data should be obtained speciﬁc to
each study’s primary and secondary research objectives.
In addition, different study designs have different
requirements for data collection; for example, epidemio-
logical studies based only on questionnaires would not
include data based on physical examination.
Table 1 lists recommendations for minimum data
collection related to characteristics of the study
population. As regards the tracking of subjects in
follow-up, we support reporting by the same standards
as in the CONSORT document for randomized clinical
trials [9].
In general, minimum data for all pelvic ﬂoor disorders
should be recorded and reported from at least ﬁve
domains [10,11]: (1) the subject’s observations (symp-
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toms); (2) quantiﬁcation of symptoms; (3) the clinician’s
observations (anatomic and functional); (4) quality of
life; and (5) socioeconomic measures.
The subject’s observations or symptoms should
include an overall assessment of the condition and
general or speciﬁc characteristics, such as quantity,
frequency or magnitude of symptoms associated with the
condition. Researchers should clearly describe the
instrument or method used to assess symptoms. There
is a critical need for reliable, validated instruments for
symptom assessment in all types of pelvic ﬂoor
disorders, which may include standardized interviews,
questionnaires, symptom diaries, and other techniques
for the collection of qualitative and quantitative data. In
addition, the extent and signiﬁcance of overlap between
symptoms of different pelvic ﬂoor disorders is poorly
understood and requires further research. For all
conditions research is needed to deﬁne categories of
improvement after intervention, including determining
patient preferences for different states (e.g. if treatment
results in resolution of the stress incontinence but also
results in the development of urgency).
Researchers should clearly describe their methods,
instruments and procedures for reporting and recording
clinical observations, and provide reliability data or
indicate its absence. As will be discussed in more detail
in the section on pelvic organ prolapse, there is a
standardized system for the quantiﬁcation (staging) of
pelvic organ prolapse based on physical examination
ﬁndings that should be used as appropriate for the
objectives of individual studies [12]. The usefulness and
validity of a simpliﬁed technique for screening for pelvic
organ prolapse should be investigated. In addition,
further research is required to determine the importance
and validity of assessment of pelvic muscle function on
physical examination. Whether speciﬁc pelvic ﬂoor
defects (sites of connective tissue or ﬁbromuscular
damage) can be reliably identiﬁed and characterized on
physical examination also needs to be determined.
Health-related quality of life is a multidimensional
construct designed to measure an individual’s perception
of the health consequences of a condition and its
subsequent treatment. Assessments include physical,
psychological and social measures; overall life satisfac-
tion; and perceptions of wellbeing. Although both
generic (overall) and condition-speciﬁc instruments
have been used to measure health-related quality of
life in women with pelvic ﬂoor disorders [13–15], more
research is required, particularly to evaluate the
sensitivity of these instruments to change after interven-
tion and to investigate the impact of coexisting
conditions. Researchers should deﬁne health-related
quality of life as it relates to their study, and clearly
describe the methods or instruments for its assessment.
Whenever possible, researchers should select instru-
ments with published reliability and sensitivity.
Socioeconomic measures should be obtained, particu-
larly to evaluate any difference in economic impact of
different interventions in controlled trials. In addition,
speciﬁc cost-effectiveness analyses may be performed to
compare the relative merits of interventions according to
the market value of goods and services required to
achieve a given health effect, with effectiveness
characterized as a speciﬁc outcome, such as alleviation
of symptoms or the restoration of function.
Pelvic Organ Prolapse
For the purposes of this discussion, pelvic organ prolapse
includes anterior vaginal prolapse (previously known as
cystocele), apical or uterine prolapse, posterior vaginal
prolapse (previously known as rectocele, enterocele, and
perineal descent; it does not include rectal prolapse.
There is as yet no large epidemiological study
evaluating the natural history of women with asympto-
matic prolapse, or the type and frequency of symptoms
in women with symptomatic prolapse. Even the
association of speciﬁc symptoms with physical exam-
ination ﬁndings of prolapse has not been well studied.
Ideally, the clinical deﬁnitions of prolapse would include
the presence and severity of symptoms, and the
distinction between cure and failure after intervention
would include the resolution or persistence of such
symptoms. However, symptoms could not be included in
these deﬁnitions until further research provides data on
the association between prolapse and symptoms, both
before and after intervention, in a large cohort of
women.
The deﬁnitions of prolapse presented here are based
on ﬁndings at physical examination. Any current
distinction between ‘normal’ physical examination
ﬁndings and ‘abnormal’ ﬁndings that constitute prolapse
is arbitrary, as data correlating symptoms to physical
ﬁndings are lacking. Many women after vaginal delivery
have some degree of ‘prolapse’ (i.e. physical examina-
Table 1. Recommendations for data collection related to character-
istics of study population
1. Age
2. Obstetric history (including parity)
3. Menopausal status
4. Race/ethnicity
5. Body mass index (weight and height)
6. Smoking status
7. Past surgical history
8. Medication use
9. Medical conditions (such as neurologic conditions, diabetes,
pulmonary conditions)
10. Functional description of physical and mental capabilities (e.g.
level of physical activity, mental status)
11. Prior therapy for pelvic ﬂoor disorders, particularly the condition
under study (including behavioral, pharmacological and/or
surgical interventions)
12. Details of subject enrollment (including total number of patients
treated for the condition of interest during the timespan of study,
number of patients evaluated for study, and number of patients
who declined participation in study and why)
13. Details of follow-up (including length of follow-up: minimum,
range, mean or median; number of subjects lost to follow-up and
why; use of statistical techniques, taking into account differing
lengths of follow-up).
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tion changes consistent with less than perfect vaginal
support). Although this might be considered ‘normal’ for
parous women, we recommend that until data are
available on which to base such a distinction, only the
complete absence of prolapse should be considered
‘normal’. Further research is necessary to determine the
importance of asymptomatic prolapse and its relation-
ship to the subsequent development of symptomatic
prolapse. In addition, we recognize that many women
who may be categorized as ‘anatomic failures’ are, in
fact, satisﬁed with their postsurgical results; we
anticipate that evidence provided by further research
will allow subsequent reﬁnement of these deﬁnitions to
take into account the relief of symptoms and patient
satisfaction, as well as anatomic outcomes.
The deﬁnitions of prolapse were not based on speciﬁc
test results, primarily because of lack of evidence. We
recommend that further research be performed to
investigate the usefulness of various tests (for example,
imaging by X-ray contrast or ultrasound) in determining
deﬁnitions and outcomes of prolapse.
Stages of prolapse are determined using the standar-
dized system of the International Continence Society
[12]. In this system measurements are made at different
vaginal sites, providing quantiﬁcation of prolapse
affecting different vaginal segments (anterior and
posterior vagina, vaginal apex or cervix) as well as an
overall stage of prolapse. Measurements are made in
centimeters relative to the hymen as the reference point;
negative numbers represent positions above the hymen,
and positive numbers represent points beyond or past the
hymen.
In general, prolapse is deﬁned as descent of stage I or
greater. An optimal anatomic outcome (cure) after
intervention is deﬁned as stage 0, or no prolapse. A
satisfactory anatomic outcome (improvement) after
intervention is deﬁned as stage I. An unsatisfactory
anatomic outcome (persistence or recurrence, failed
treatment) after intervention is deﬁned as stage II or
greater, or no change or worsening from the pre-
treatment stage. Speciﬁc deﬁnitions for individual
conditions of prolapse are listed in Table 2.
Enterocele is deﬁned as a cul de sac abnormality
containing peritoneum and intra-abdominal contents,
and involving the apical, anterior or posterior compart-
ments of the vagina. Enterocele may be a separate entity
from apical prolapse. Cure of enterocele should be
deﬁned in terms of correction in the anatomic
compartment (e.g. vaginal apex or posterior vagina).
Further research is needed to investigate different types
of enterocele.
Bladder neck position should be described as a
continuum (not as a dichotomy of ‘normal’ versus
‘abnormal’) using one of a variety of methods, such as
the cotton swab test, ultrasound or other methods.
Similarly, perineal descent should be described as a
continuum (not as a dichotomy) using one of a variety of
methods, such as defecography, ultrasound, perineome-
try or magnetic resonance imaging (MRI). Bladder neck
position and perineal position can be measured at rest,
Table 2. Deﬁnitions of apical or uterine prolapse, anterior vaginal
prolapse and posterior vaginal prolapse
Apical or uterine prolapse
Deﬁnition
Descent of the vaginal apex (posthysterectomy) or cervix to within 1 cm
of the hymen or lower; stage I or worse by ICS* staging, with point C
more than 2 cm lower than TVL{ (quantiﬁcation value for point C at
least 7(TVL73) cm or lower)
Optimal anatomic outcome (cure)
No prolapse of the vaginal apex or cervix is demonstrated; stage 0 by
ICS staging, with point C between 7TVL and 7(TVL72) cm
(quantitation value for point C 4[TVL72] cm)
Satisfactory anatomic outcome (improvement)
Descent of the vaginal apex or cervix to within 1 cm above the hymen;
stage I by ICS staging, with point C between 2 cm lower than TVL and
1 cm above the hymen (quantitation value for point C between
7[TVL72] and 71 cm)
Unsatisfactory anatomic outcome (persistence or recurrence, failed
treatment)
Descent of the vaginal apex or cervix to 1 cm proximal to the hymen or
lower, or no change, or worsening from pre-treatment stage; stage II or
worse by ICS staging, with point C 71 cm or lower, or no change or
worsening from pre-treatment position
Anterior vaginal prolapse
Deﬁnition
Descent of the anterior vagina to within 1 cm of the hymen or lower;
stage I or worse by ICS staging, with point Aa or Ba at72 cm or lower
Optimal anatomic outcome (cure)
No prolapse of the anterior vagina is demonstrated; stage 0 by ICS
staging, with points Aa and Ba at 73 cm
Satisfactory anatomic outcome (improvement)
Descent of the anterior vagina to within 1 cm above the hymen; stage I
by ICS staging, with point Aa or Ba at 72 cm
Unsatisfactory anatomic outcome (persistence or recurrence, failed
treatment)
Descent of the anterior vagina to 1 cm proximal to the hymen or lower,
or no change or worsening from pre-treatment stage; stage II or worse
by ICS staging, with point Aa or Ba at71 cm or lower, or no change or
worsening from pre-treatment position
Posterior vaginal prolapse
Deﬁnition
Descent of the posterior vagina to within 1 cm of the hymen or lower;
stage I or worse by ICS staging, with point Ap or Bp at72 cm or lower
Optimal anatomic outcome (cure)
No prolapse of the posterior vagina is demonstrated; stage 0 by ICS
staging, with points Ap and Bp at 73 cm
Satisfactory anatomic outcome (improvement)
Descent of the posterior vagina to within 1 cm above the hymen; stage I
by ICS staging, with point Ap or Bp at 72 cm
Unsatisfactory anatomic outcome (persistence or recurrence, failed
treatment)
Descent of the posterior vagina to 1 cm proximal to the hymen or lower,
or no change or worsening from pre-treatment stage; stage II or worse
by ICS staging, with points Ap or Bp at71 cm or lower, or no change
or worsening from pre-treatment position
* ICS, International Continence Society; {TVL, total vaginal length.
Point Aa represents a point on the anterior vagina 3 cm proximal to the
external urethral meatus; by deﬁnition, its value is 73 cm in the absence
of prolapse and has a maximum of +3 cm.
Point Ba represents the most distal extent of prolapse affecting the anterior
vagina; by deﬁnition, its value is73 cm in the absence of prolapse and has
a maximum positive value of the total vaginal length.
Point C represents the most distal edge of the cervix or vaginal cuff
(posthysterectomy).
Point Ap represents a point on the posterior vagina 3 cm proximal to the
hymen; by deﬁnition, its value is 73 cm in the absence of prolapse and
has a maximum of +3 cm.
Point Bp represents the most distal extent of prolapse affecting the
posterior vagina; by deﬁnition, its value is 73 cm in the absence of
prolapse and has a maximum positive value of the total vaginal length
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with the Valsalva maneuver (bearing down or straining),
or with pelvic muscle contraction. Further research is
needed to standardize the methods currently used to
measure bladder neck position and perineal position, and
to draw clinically meaningful distinctions between
normal and abnormal positions.
In addition to the recommendations for minimum data
collection for all subjects with pelvic ﬂoor disorders, we
recommend that the physical examination for research
subjects in studies of pelvic organ prolapse include: (1)
the use of the standardized quantiﬁcation system for
staging of prolapse [12]; (2) rectovaginal and anal
sphincter examination; (3) assessment of the presence or
absence of pelvic muscle contraction; and (4) a screen-
ing pelvic neurologic examination (which could include
one of a variety of methods, such as bulbocavernosus
reﬂex, anal wink response, anal sphincter tone or anal
sphincter contraction). As mentioned above, further
research is required to determine the usefulness and
validity of assessment of pelvic muscle function on
physical examination; and to determine the role of
testing in deﬁning conditions and response to interven-
tion for pelvic organ prolapse.
Urinary Incontinence and Other Urinary
Symptoms
Urinary incontinence may occur as a solitary symptom,
as in stress urinary incontinence, or as part of a symptom
complex, e.g. when urge urinary incontinence is
accompanied by urgency and frequency. The Interna-
tional Continence Society [16] has developed standard
deﬁnitions and introduced the concept of incontinence as
a symptom (e.g. for stress incontinence the patient says
she loses urine on coughing), a sign (the patient is seen
to leak when coughing during physical examination),
and a condition (genuine stress incontinence, when the
patient fulﬁlls the deﬁnition during urodynamic studies).
Therefore, in International Continence Society terms the
condition represents a deﬁnitive diagnosis and requires
the use of urodynamic studies, with measurement of both
intravesical and intra-abdominal pressure.
In this section, existing International Continence
Society deﬁnitions are used except where stated. In
general, urinary incontinence of all types is deﬁned as
involuntary loss of urine that is both objectively
demonstrable and a social or hygienic problem for the
patient. The following two sections describe stress and
urge urinary incontinence as separate entities; however,
the conditions commonly coexist (mixed incontinence).
Further research is needed to better deﬁne the overlap in
conditions, to determine whether it is feasible to
distinguish between types of symptoms by questionnaire
or voiding diary and, if so, how this can best be
quantiﬁed.
Stress Urinary Incontinence
The symptom of stress urinary incontinence indicates
the patient’s or caregiver’s statement of involuntary loss
of urine during physical exertion. The sign of stress
urinary incontinence is the objective demonstration of
loss of urine synchronous with physical exertion. The
condition of genuine (urodynamic) stress incontinence
is the involuntary loss of urine occurring as a result of a
rise in intra-abdominal pressure, in the absence of a
detrusor contraction (modiﬁed from the International
Continence Society deﬁnition).
Subcategories of stress incontinence are in common
clinical and research use, including types based on
urethral mobility (hypermobility versus ﬁxed urethral
position) and urethral function (commonly measured as
urethral pressure or leak-point pressure, and described by
the term ‘intrinsic sphincter deﬁciency (ISD)’ when
abnormal). However, at present there are insufﬁcient
data on which to base the valid deﬁnition of such
subcategories. Further research is needed to deﬁne
characteristics of normal and abnormal urethral position
and function, and to determine how these characteristics
relate to the pathophysiology and optimal clinical
management of stress incontinence.
Outcome after treatment should be deﬁned in terms of
stress urinary incontinence, but also in terms of
associated symptoms and unwanted (side) effects
resulting from an intervention, after a return to baseline
activities and medications. Cure of stress urinary
incontinence is deﬁned as: (1) resolution of the stress
incontinence symptoms; (2) resolution of the sign
(negative full bladder cough stress test, performed
under the same conditions as before treatment); and (3)
no new symptoms or side effects. New symptoms or side
effects should be speciﬁcally described and could
include new urinary symptoms such as urinary urgency,
frequency, urge incontinence, with or without urody-
namic changes of detrusor overactivity (detrusor
instability); change in sexual function; development or
worsening of pelvic organ prolapse; adverse effect on
bowel function; onset of urinary tract infections; surgical
complications, such as foreign-body reaction to grafts,
the development of ﬁstula or diverticula; osteitis or
osteomyelitis; neuropathy; and others. In studies using
urodynamics after intervention the absence of genuine
stress incontinence should be documented.
Failure of treatment of stress urinary incontinence is
deﬁned as persistent stress symptoms with the number of
incontinent episodes unchanged, or worse, by voiding
diary, plus a positive full bladder cough stress test
(performed under the same conditions as before
treatment), or genuine stress incontinence conﬁrmed by
urodynamic studies, with or without new symptoms or
side effects.
Between the two extremes of cure and failure we
recognize the value of a category for subjects who are
improved. Improvement includes persistent stress symp-
toms but with the number of incontinent episodes
decreased by voiding diary, plus a positive full bladder
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cough stress test (performed under the same conditions
as pre-treatment) or genuine stress incontinence con-
ﬁrmed by urodynamic studies, with or without new
symptoms or side effects. However, further research is
required before clinically meaningful categories of
improvement can be deﬁned. It would be particularly
valuable to deﬁne levels of improvement considered
important to the patient, and to determine how to best
measure such a change. For example, if a change in the
number of incontinent episodes is an important measure
of improvement, is this better quantiﬁed as an absolute
number of leak episodes after treatment, or as a
percentage change from baseline? In addition, when
more than one characteristic is used to deﬁne an outcome
(i.e. symptoms and signs), the characteristics will not be
concordant in some situations. Possible categories to
describe these situations include patient-observed treat-
ment effect, with absence of stress symptoms and no side
effects, but a positive full bladder cough stress test; and
provider-observed treatment effect, with persistence of
stress symptoms, no side effects and a negative full
bladder cough stress test.
Urge Urinary Incontinence
Urge urinary incontinence usually occurs with other
lower urinary tract symptoms. Therefore, each symptom
is deﬁned as follows. Frequency is the statement that the
patient voids eight or more times in 24 hours. Nocturia
is the statement that the patient wakes from sleep in
order to pass urine. Urgency is the statement that the
patient feels a strong need to pass urine for fear of
leakage. Urge urinary incontinence is the report that
the patient has involuntary loss of urine associated with a
feeling of urgency (modiﬁed from the International
Continence Society deﬁnition). Nocturnal enuresis
denotes loss of urine during sleep. The term ‘overactive
bladder’ has been coined to describe symptoms
suggestive of detrusor overactivity (detrusor instability),
and is deﬁned as urgency and/or urge incontinence,
usually occurring with urinary frequency, in the absence
of local pathological or metabolic factors (such as
urinary tract infection or polyuria with diabetes).
For outcomes related to symptoms, cure is deﬁned as
the patient’s statement that the symptom(s) is no longer
present. In the case of frequency, there are seven or
fewer micturitions per 24 hours. Failed treatment is
deﬁned as the patient’s statement that the symptom(s) is
no better or worse, with objective data from a urinary
diary. As discussed above, the category of improvement
cannot be speciﬁcally deﬁned at present and requires
further research to deﬁne outcomes of value to patients.
Improvement could include the patient’s statement that
the symptom(s) is less frequent or less troublesome with
evidence from a urinary diary.
Detrusor overactivity (detrusor instablity and hyperre-
ﬂexia) is a urodynamic diagnosis characterized by
involuntary phasic detrusor contractions during the
ﬁlling phase of cystometry, which may be spontaneous
or provoked, and which the patient cannot completely
suppress. The detrusor contractions may be provoked by
rapid ﬁlling, alterations of posture, coughing, walking,
jumping, or other provocative maneuvers. Outcomes for
detrusor overactivity should be deﬁned separately for
symptoms, as described above, and for urodynamic
ﬁndings. Cure of detrusor overactivity is deﬁned as the
absence of involuntary phasic detrusor contractions on
ﬁlling cystometry. Failure is deﬁned as unimproved or
worsened detrusor overactivity on urodynamics. Again,
the deﬁnition of improvement cannot be speciﬁed but, if
used, the method of measurement should be precisely
deﬁned.
Minimum Dataset for Urinary Incontinence and Other
Urinary Symptoms
In addition to the recommendations for minimum data
collection for all subjects with pelvic ﬂoor disorders, we
recommend that studies of urinary incontinence and
other urinary symptoms include: (1) a urinary diary for
at least 3 days per episode of data collection, recording
and reporting (as a minimum) pad use, urinary
incontinence episodes and urinary frequency; (2)
physical examination to include (a) screening for
pelvic organ prolapse (in some studies, such as surgical
studies of stress urinary incontinence, the standardized
quantiﬁcation system for staging of prolapse [12] should
be used; (b) rectal examination; (c) assessment of the
presence or absence of pelvic muscle contraction; and
(d) a screening pelvic neurologic examination (which
could include one of a variety of methods, such as
bulbocavernosus reﬂex, anal wink response, anal
sphincter tone or anal sphincter contraction); (3)
postvoid residual urine volume measurement; (4) testing
to evaluate for urinary tract infection; and (5)
urodynamic studies to include (a) a full bladder cough
stress test to elicit the sign of stress urinary incontinence;
and (b) ﬁlling cystometry. For surgical studies of stress
urinary incontinence, if measures of urethral mobility
and function are used the methodology should be
speciﬁed precisely. Further research is needed to clarify
the role of pad tests in quantifying symptom severity and
response to treatment; if pad tests are used, the
methodology should be described in detail.
Posterior Pelvic Floor Dysfunction (including
Fecal Incontinence)
Women with other pelvic ﬂoor disorders frequently have
coexistent problems with the posterior pelvic ﬂoor,
which may include fecal incontinence, fecal urgency,
constipation, chronic pain (such as levator syndrome or
proctalgia fugax), solitary rectal ulcer syndrome and
rectal prolapse. These are among the most understudied
of all pelvic ﬂoor disorders. Because of lack of evidence,
our recommendations are much less speciﬁc for this
group of disorders than for pelvic organ prolapse and
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urinary incontinence. There are some accepted deﬁni-
tions for symptoms and conditions of posterior pelvic
ﬂoor dysfunction, but further research is needed to assess
whether they are applicable to the group of women with
pelvic ﬂoor disorders. Therefore, the following deﬁni-
tions are very broad; we anticipate that future research
ﬁndings will guide the development of more speciﬁc
deﬁnitions.
Fecal Incontinence
For the purposes of this discussion, fecal incontinence
includes incontinence of either feces or gas. Although
there is an assumption in the literature that incontinence
of formed stool represents a more severe form of fecal
incontinence than incontinence of liquid stool (and
similarly, that incontinence of liquid stool represents a
more severe form of fecal incontinence than incon-
tinence of gas) [17], there are minimal data to support
this. We have preserved the distinction between different
types of loss (based solely on the patient’s description) in
our deﬁnitions, but further research is required to
conﬁrm or refute this. Our deﬁnitions of fecal
incontinence are based on symptoms. There are many
systems that quantify symptoms related to fecal
incontinence [18]; however, an internationally agreed
scoring and evaluation system does not yet exist. This
lack of consensus makes it difﬁcult to compare ﬁndings
across studies. We identiﬁed this need for a standardized
system of evaluation and quantiﬁcation of symptoms
(which may include questionnaires, diaries and quality
of life assessment) as a high priority for further research
in this ﬁeld. In contrast to urinary incontinence, the
objective demonstration of fecal incontinence has not
been a component of deﬁnitions to date. In addition, as
with pelvic organ prolapse, speciﬁc test results were not
included as part of the deﬁnitions (although certain tests
may be useful in determining the etiology of different
subcategories of fecal incontinence).
A deﬁnition for fecal incontinence commonly used in
the colorectal literature is ‘the inability to defer
defecation until a socially acceptable time’. This
deﬁnition was felt to be deﬁcient for deﬁning fecal
incontinence in women with pelvic ﬂoor disorders in
several respects. First, it does not differentiate between
true loss of stool and functional disorders that may
compromise the ability to defer defecation but not
represent true incontinence, such as diarrhea or fecal
urgency. Second, it does not require a negative impact
on the patient’s lifestyle, which was felt to be an
important component of our deﬁnition. As with urinary
incontinence, the number of episodes of fecal incon-
tinence was felt to be an important indicator of severity
but not a component of the deﬁnition itself. We
recommend that researchers report the number of
incontinent episodes by time frame of interest and the
character of loss (solid stool, liquid stool, gas).
Deﬁnitions for fecal incontinence are listed in Table 3.
In deﬁning the impact of interventions on fecal
incontinence, cure was deﬁned as complete resolution
of the symptom. Failed treatment (persistence or
recurrence) was deﬁned as no improvement or a
worsening of symptoms. As with the other pelvic ﬂoor
disorders, improvement could not be speciﬁcally deﬁned
but could include some favorable change in symptoms
that may be based on quality of life measures, frequency
of symptoms and consistency of loss. Further research is
needed to develop clinically meaningful levels of
improvement after intervention.
Constipation
Constipation is a symptom with many different
deﬁnitions, based on stool frequency, consistency, the
need for straining, incomplete emptying, other char-
acteristics, or some combination [19–21]. Without a
standard accepted deﬁnition of constipation and without
evidence that these deﬁnitions are applicable to the
Table 3. Deﬁnitions of fecal incontinence
Incontinence of formed stool
Deﬁnition
Recurring episodes of involuntary loss of formed stool that is a social or
hygienic problem. The time frame of interest and the character of loss
should be speciﬁed.
Cure
Patient statement of no involuntary loss of formed stool within the stated
time frame.
Improvement
Favorable change based on outcome measures to be developed,
including quality of life, frequency of symptoms, consistency of loss,
socioeconomic factors, etc.
Persistence/recurrence (failed treatment)
No improvement or worsening of symptoms.
Incontinence of liquid stool
Deﬁnition
Recurring episodes of involuntary loss of liquid stool that is a social or
hygienic problem. The time frame of interest and the character of loss
should be speciﬁed.
Cure
Patient statement of no involuntary loss of liquid stool within the stated
time frame.
Improvement
Favorable change based on outcome measures to be developed,
including quality of life, frequency of symptoms, consistency of loss,
socioeconomic factors, etc.
Persistence/recurrence (failed treatment)
No improvement or worsening of symptoms.
Incontinence of gas
Deﬁnition
Recurring episodes of involuntary loss of gas that is a social or hygienic
problem. The time frame of interest and the character of loss should be
speciﬁed.
Cure
Patient statement of no involuntary loss of gas within the stated time
frame.
Improvement
Favorable change based on outcome measures to be developed,
including quality of life, frequency of symptoms, consistency of loss,
socioeconomic factors, etc.
Persistence/recurrence (failed treatment)
No improvement or worsening of symptoms.
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population of women with pelvic ﬂoor disorders, we
recommend that further research be performed before
developing such a deﬁnition.
Fecal Urgency
Fecal urgency is a symptom rather than a condition. The
Rome diagnostic criteria for functional bowel disorders
considers fecal urgency to be a supportive symptom for
the diagnosis of irritable bowel syndrome, deﬁned as
‘having to rush to have a bowel movement’ [21]. In
parallel to wording related to urinary urgency, we
suggest the deﬁnition of fecal urgency be ‘the patient’s
statement of overwhelming desire to defecate accom-
panied by fear of leakage of bowel contents’. However,
further research is required to test this or other
deﬁnitions before recommendations can be made.
Minimum Dataset
In addition to the recommendations for minimum data
collection for all subjects with pelvic ﬂoor disorders, we
recommend that studies of posterior pelvic ﬂoor
dysfunction include physical examination with (1)
screening for pelvic organ prolapse (in some studies,
such as surgical studies of fecal incontinence, the
standardized quantiﬁcation system for staging of
prolapse [12] should be used); (2) rectal examination;
(3) assessment of the presence or absence of pelvic
muscle contraction; and (4) a screening pelvic neurolo-
gic examination (which could include one of a variety of
methods, such as bulbocavernosus reﬂex, anal wink
response, anal sphincter tone or anal sphincter contrac-
tion). At present there are insufﬁcient data to make
recommendations for minimum testing. Particularly for
surgical studies of fecal incontinence, researchers are
encouraged to consider imaging of the anal sphincters
(e.g. with anal endosonography) and some type of
neurophysiologic testing (such as electromyography or
other tests). Further research is needed to deﬁne the role
of testing in the evaluation and management of posterior
pelvic ﬂoor dysfunction.
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EDITORIAL COMMENT: This is a compilation of
opinions regarding the need for standardization of
terminology for pelvic ﬂoor dysfunction. Some of their
deﬁnitions may or may not be appropriate, however, we
are now in the process of deﬁning what represents prolapse
versus normal, and what represents a cure after interven-
tion versus persistence. Hopefully this document will serve
as a starting point to allow for further discussions and
revisions of these deﬁnitions as we study this complex
problem.
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